TKMR News 22.81 10/17/2014 05:44:56 Tekmira Pharmaceuticals Corp

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tekmira Pharmaceuticals Corp (TKMR) 22.81 $TKMR

Tekmira Presents Data on Hepatitis B Candidate TKM-HBV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:30PM CDT
Tekmira Pharmaceuticals Corporation (TKMR) presented encouraging preclinical data on its hepatitis B infection candidate, TKM-HBV.
MDVN: 92.54 (+2.91), AUXL: 30.35 (-0.06), LGND: 48.86 (+2.58), TKMR: 22.81 (-1.09)

Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
M2 - Thu Oct 16, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Toyama Chemical Co., Ltd. - Crucell N.V. - Medicago Inc. - NanoViricides, Inc. - BioCryst Pharmaceuticals, Inc. - Summit Corporation plc - AlphaVax, Inc. - Chimerix, Inc. - Microbiotix, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Vaxart, Inc. - Profectus BioSciences, Inc. - Navigen Pharmaceuticals, Inc. - Inhibikase Therapeutics, Inc. - Humabs BioMed SA - Mapp Biopharmaceutical, Inc. - NewLink Genetics Corporation - Epirus Biopharmaceuticals, Inc. Drug Profiles - Recombinant Vector Vaccine for Multivalent Filovirus - TKM-100802 - brincidofovir - favipiravir - Filovirus Vaccine - Drugs for Ebola and Marburg Infections - SMT-15000 - panfilovirus vaccine - BCX-4430 - ET-007 - ZMapp - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - ZMAb - MVA-BN-Filoviruses Vaccine - ebola virus vaccine - ebola and marburg vaccine (trivalent) - TKM-100701 - MMCatLMC - ebola and marburg rabies vaccine - Monoclonal Antibodies for Viral Infections - imatinib mesylate - oxocarbazate - thiocarbazate - EMER-IT - Ebola Vaccine - Synthetic Peptides for Ebola Virus - Monoclonal Antibodies for Ebola and Marburg Infections - ARD-5 - 1-E703 For more information visit http://www.researchandmarkets.com/research/mz...bola_viral
INO: 11.84 (+0.60), BCRX: 12.18 (+0.22), CMRX: 35.40 (+3.22), NLNK: 31.87 (+6.43), TKMR: 22.81 (-1.09), NNVC: 3.79 (+0.11), GSK: 42.88 (-0.25)

Tekmira Presents Results of Preclinical Studies With Hepatitis B Therapeutic
GlobeNewswire - Wed Oct 15, 2:30PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today the presentation of preclinical results characterizing TKM-HBV, a therapeutic agent targeting human hepatitis B virus (HBV), at the 10 Annual Meeting of the Oligonucleotide Therapeutics Society. Tekmira's Chief Technical Officer, Dr. Ian MacLachlan delivered a podium presentation titled, "Update on the Preclinical Development of an LNP-Based HBV Therapeutic." The conference is taking place in San Diego, California, from October 12 - 15, 2014.
TKMR: 22.81 (-1.09), TKM.TO: 25.58 (-1.12)

Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver
PR Newswire - Wed Oct 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, TKMR, GILD, DDD and TASR.
TSLA: 226.35 (-3.35), GILD: 96.88 (+0.72), DDD: 40.90 (-0.37), TKMR: 22.81 (-1.09), TASR: 14.97 (+0.28)

Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene
PR Newswire - Wed Oct 15, 8:10AM CDT
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Arrowhead Research Corporation (NASDAQ: ARWR), Chimerix Inc. (NASDAQ: CMRX), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, October 14, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,315.19, down 0.04% and the NASDAQ Composite closed at 4,227.17, up 0.32%. The S&P 500 finished the session 0.16% higher at 1,877.70. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, whereas the index has advanced 9.89% on YTD basis. Register for your complimentary reports on these five stocks at:
CMRX: 35.40 (+3.22), ARWR: 7.02 (+0.55), IMGN: 8.38 (-0.38), TKMR: 22.81 (-1.09), CELG: 86.38 (-0.17)

Tekmira provides encouraging clinical data for LNP-Enabled Patisiran at the American Neurological Association's 2014 Annual Meeting
M2 - Tue Oct 14, 7:23AM CDT
Biopharmaceutical company Tekmira Pharmaceuticals (NasdaqCM:TKMR) (TSX:TKM.TO) pn Tuesday announced its six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP).
ALNY: 84.94 (+0.55), TKMR: 22.81 (-1.09)

Tekmira's Partner Reports Positive Clinical Data for LNP-Enabled Patisiran
GlobeNewswire - Mon Oct 13, 11:45PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP). Patisiran (ALN-TTR02) is an RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology.
ALNY: 84.94 (+0.55), TKMR: 22.81 (-1.09), TKM.TO: 25.58 (-1.12)

Is the U.S. Prepared to Handle Ebola?
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 12, 12:45PM CDT
Source: National Nurses United  The passing of Eric Duncan, the first patient diagnosed with Ebola in the U.S., 10 days after being admitted to Texas Health Presbyterian Hospital, is a stark reminder of Ebola's insidious nature. It's a tough to...
CAH: 72.13 (-1.10), KMB: 105.04 (-0.37), TKMR: 22.81 (-1.09), SRCL: 117.12 (+0.97), GSK: 42.88 (-0.25), OMI: 32.24 (+0.06)

'Fast Money' Recap: How to Trade in a Volatile Marketplace
at The Street - Fri Oct 10, 4:00AM CDT
The trading panel discussed defensive trades, the state of the market and whether Carl Icahn is right about Apple.
TSLA: 226.35 (-3.35), LO: 58.00 (-0.72), XOM: 90.60 (+0.38), TKMR: 22.81 (-1.09), PANW: 97.88 (+0.45), TLT: 121.75 (-0.78), PEP: 90.79 (-0.98), T: 33.64 (-0.23), CMRX: 35.40 (+3.22), RIG: 30.15 (+0.71), AAL: 32.97 (+1.28), GOOGL: 536.92 (-3.81), TWTR: 48.23 (-1.76), AAPL: 96.26 (-1.28), AMZN: 302.86 (-3.11), FB: 72.63 (-0.58), SYMC: 22.03 (-0.12), TOT: 54.85 (-0.43), TSO: 59.81 (+1.17), CVEO: 12.40 (-0.31), IWM: 107.80 (+1.20), GPS: 36.49 (+0.55), CVX: 111.06 (+1.79), GG: 23.88 (+0.24)

Chimerix Falls as Ebola Patient on Brincidofovir Dies in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 3:30PM CDT
Chimerix 's (CMRX) brincidofovir failed to save the Ebola patient.
MDVN: 92.54 (+2.91), BCRX: 12.18 (+0.22), CMRX: 35.40 (+3.22), TKMR: 22.81 (-1.09)

Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear
at Investor's Business Daily - Thu Oct 09, 1:38PM CDT
Lakeland Industries (LAKE) shares soared Thursday after a Dallas County sheriff's deputy was put in isolation with possible Ebola symptoms, raising fears the deadly virus may be spreading in the U.S. The company makes the ChemMax 1 hazmat suit, which...
CMRX: 35.40 (+3.22), HEB: 0.32 (-0.01), NLNK: 31.87 (+6.43), TKMR: 22.81 (-1.09), LAKE: 20.69 (-2.91), GSK: 42.88 (-0.25)

Tekmira to Present HBV Pre-Clinical Data at Meeting of the Oligonucleotide Therapeutics Society
GlobeNewswire - Thu Oct 09, 12:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Ian MacLachlan, Tekmira's Executive Vice President and Chief Technical Officer, will present preclinical data for TKM-HBV, the Company's product candidate targeting hepatitis B virus, at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. The presentation will take place on Wednesday, October 15, 2014 at 12 pm (PT) / 3 pm (ET) in San Diego at The Hilton San Diego Resort and Spa.
TKMR: 22.81 (-1.09), TKM.TO: 25.58 (-1.12)

'Fast Money Halftime Report': U.S. Stocks Rebound, but Traders Look for a Pullback
at The Street - Wed Oct 08, 2:44PM CDT
The trading panel discusses energy and retail stocks, as well as whether the market has further downside ahead. GM CEO Mary Barra, a guest, talked about GM's future.
GPRO: 72.69 (-0.18), DFE: 48.16 (-0.50), F: 13.98 (+0.36), DUK: 78.17 (-0.73), GBX: 52.95 (+3.47), DAL: 33.32 (+0.94), TKMR: 22.81 (-1.09), DIS: 81.74 (-0.34), SMH: 46.42 (+0.55), SHLD: 30.00 (+0.44), CMRX: 35.40 (+3.22), SRPT: 22.30 (+1.39), TGT: 59.44 (-0.54), JCP: 7.30 (+0.21), COST: 122.95 (-1.35), GM: 29.94 (+0.25), LAKE: 20.69 (-2.91), XLE: 82.00 (+1.44)

Stock Market Today: Stocks Spike as Fed Minutes Allay Fears of Rate Hike
at The Street - Wed Oct 08, 1:24PM CDT
U.S. stocks popped on Wednesday after the release of the Federal Reserve minutes which allayed fears an interest rate hike could come sooner than expected.
ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), MON: 110.66 (+1.83), VMW: 88.60 (-0.97), WMT: 73.82 (-1.38), TKMR: 22.81 (-1.09), SHLD: 30.00 (+0.44), AGN: 178.00 (+0.41), GTAT: 0.44 (+0.03), CMRX: 35.40 (+3.22), JCP: 7.30 (+0.21), EMC: 26.89 (-0.38), AAPL: 96.26 (-1.28), YUM: 67.62 (+0.39)

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies
at The Street - Wed Oct 08, 11:32AM CDT
The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.
INO: 11.84 (+0.60), BCRX: 12.18 (+0.22), CMRX: 35.40 (+3.22), HEB: 0.32 (-0.01), SRPT: 22.30 (+1.39), NLNK: 31.87 (+6.43), TKMR: 22.81 (-1.09), LAKE: 20.69 (-2.91), GSK: 42.88 (-0.25)

Tekmira Pharmaceuticals (TKMR) Is Strong On High Volume Today
at The Street - Wed Oct 08, 10:35AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a strong on high relative volume candidate
TKMR: 22.81 (-1.09)

The Disgusting Reaction to Ebola Patient's Death by Tekmira, Chimerix Traders
at The Street - Wed Oct 08, 10:33AM CDT
Tekmira shares surge after Thomas Duncan's death announced.
CMRX: 35.40 (+3.22), TKMR: 22.81 (-1.09)

Revised Guidance, Development Milestones, Appointment, Program Extension, and Event Schedules - Research Reports on Mylan, Tekmira, GSK, Cigna and WellPoint
PR Newswire - Wed Oct 08, 8:00AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), GlaxoSmithKline plc (NYSE: GSK), Cigna Corp. (NYSE: CI) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7013-100free.
CI: 88.03 (-0.70), TKMR: 22.81 (-1.09), MYL: 48.77 (+1.39), GSK: 42.88 (-0.25), WLP: 111.92 (+0.86)

'Fast Money' Recap: What Should You Buy in a Declining Market?
at The Street - Wed Oct 08, 4:00AM CDT
The trading panel discusses Yum! Brands, the mining industry and Ebola treatments.
PEI: 19.46 (+0.31), CLR: 55.92 (+2.07), GMCR: 137.98 (-1.63), TKMR: 22.81 (-1.09), IBB: 260.98 (+4.51), M: 56.57 (+0.57), JBLU: 11.22 (+0.92), UPS: 95.63 (-0.82), PEP: 90.79 (-0.98), SBUX: 72.64 (+0.26), AGN: 178.00 (+0.41), SAVE: 55.66 (+1.69), CMRX: 35.40 (+3.22), EOG: 91.27 (+3.10), DPZ: 83.93 (+0.28), COST: 122.95 (-1.35), GOOGL: 536.92 (-3.81), CMLS: 3.57 (+0.28), AAPL: 96.26 (-1.28), MBLY: 46.46 (+1.11), YUM: 67.62 (+0.39), APC: 89.57 (+4.11), AMBA: 38.76 (+0.16), AEC: 18.52 (-0.09), GPRO: 72.69 (-0.18), ETN: 59.92 (+0.95), IR: 54.91 (+0.97), GSK: 42.88 (-0.25), PXD: 177.92 (+6.34), MCD: 89.91 (-0.53), GM: 29.94 (+0.25), IWM: 107.80 (+1.20), SODA: 21.09 (-0.12)

Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 07, 6:00PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TTS: 8.56 (-0.06), OLED: 29.86 (-0.22), EZPW: 9.55 (+0.16), CONN: 30.23 (+0.30), ADHD: 5.58 (+0.13), LINTB: 30.07 (+1.98), GWGH: 8.97 (+0.04), LINTA: 29.92 (+1.79), TKMR: 22.81 (-1.09), AEGN: 17.30 (+0.21), UCTT: 8.09 (unch), TKM.TO: 25.58 (-1.12)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 115

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 55

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 123

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 77

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 114

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

Anivive's Lab Expansion: Driving Innovation in Veterinary Diagnostics

Updated Category News Views 130

Expanding Horizons in Veterinary Diagnostics Anivive is embarking on an exciting journey as it expands its state-of-the-art laboratory, a move that reflects the soaring demand for its specialized pathology services. This enhancement comes in response to the growing interest in veterinary diagnostics, particularly through its subsidiary, Vidium, known for its leadership in...

Continue Reading
Aurora Chen Joins PBGH as Vice President to Lead Advisory Services

Updated Category News Views 239

Aurora Chen Joins PBGH as Vice President of Advisory Services PBGH, a notable nonprofit coalition, has proudly announced the appointment of Aurora Chen as its Vice President of Advisory Services. Bringing a wealth of experience in the health care and employee benefits sector, Chen is set to lead efforts that expand and enhance the advisory services offered by PBGH. This...

Continue Reading
What Are the Pros and Cons of Using a Financial Planner?

Updated Category Personal Finance Views 654

Are you considering enlisting the help of a financial planner and aren’t sure if it's the right choice for you? Then you need to know about their pros and cons! Financial planners play a vital role in offering you support and guidance with tailor-made plans that help you meet your savings, retirement, or investment goals. We have outlined the pros and cons of a...

Continue Reading
Angel Oak Financial Strategies Trust Announces March 2025 Dividend

Updated Category News Views 113

Introduction to Angel Oak Financial Strategies Income Term Trust Angel Oak Financial Strategies Income Term Trust (FINS) has declared a monthly distribution that investors eagerly anticipate. The closed-end fund listed on the New York Stock Exchange is making headlines as it announces a distribution of $0.109 per share for March. Understanding the mechanics behind such...

Continue Reading
Investors Eye Value Stocks as Federal Reserve Makes Moves

Updated Category News Views 81

Exploring Value Stocks Amid Federal Adjustments Bank of America has underscored three key sectors that stand to gain from the Federal Reserve's unique dual approach of cutting interest rates while profits rise in corporate sectors. This 'rare double whammy of stimulus' could present a significant opportunity for savvy investors keen on value stocks. Key Sector Highlights...

Continue Reading